NEW ORLEANS (WVUE) - If you have trouble affording prescription drugs, some independent pharmacists say that so-called ...

More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat. Bristol has created a strong pipeline ...

The company's position is bolstered by strong performers like Eliquis, but it also faces challenges from both branded competitors and the looming threat of generic competition. The impact of the ...

This was partly offset by a 1% rise in the company’s revenue from $46 billion to $47 billion over the same period; and a 4.1% ...

The biopharma industry is on an upward trajectory, driven by groundbreaking advances in treatment options and a rising demand ...

Bristol Myers Squibb reported a higher-than-expected third-quarter profit on Thursday, citing strong sales of established ...

On Thursday, Bristol Myers Squibb & Co (NYSE:BMY) posted third-quarter revenues of $11.89 billion, beating the consensus of ...

Discontinuing eliquis in patients without adequate continuous anticoagulation increases risk of stroke. The most common side effect is bleeding. Other side effects include bleeding in the stomach ...

Bristol Myers Squibb Co. raised its 2024 earnings guidance after reporting better-than-expected revenue and profit, fueled by demand for the blood-thinner Eliquis and several newer treatments.Adjusted ...

sales are likely to have been hurt by generic competition in some international markets due to the loss of patent exclusivity. The Zacks Consensus Estimate for alliance revenues from Eliquis is $1 ...

Following Keytruda, Bristol-Myers Squibb (BMS) and Pfizer's Eliquis (apixaban), an oral anticoagulant, will be the second best-selling drug out of the top ten, with annual sales of $18.7 billion ...